peptides.api

CJC-1295 DAC

discontinued

Also known as: CJC-1295 with Drug Affinity Complex

Albumin-binding (DAC) GHRH analog producing sustained, multi-day elevation of GH and IGF-1.

Key data

Category
Growth Hormone Peptides
Half-life
6-8 days
Administration
subcutaneous
Research status
discontinued
References
31
Tags
ghrh-analog, long-acting

Research & studies

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
International journal of molecular sciences · 2026 · PubMed
A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS
Drug testing and analysis · 2019 · PubMed
An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma
Drug testing and analysis · 2019 · PubMed
Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions
Substance use & misuse · 2016 · PubMed
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation
Drug testing and analysis · 2010 · PubMed
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2009 · PubMed
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
The Journal of clinical endocrinology and metabolism · 2006 · PubMed
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
American journal of physiology. Endocrinology and metabolism · 2006 · PubMed

Frequently asked questions

What is CJC-1295 DAC?

Albumin-binding (DAC) GHRH analog producing sustained, multi-day elevation of GH and IGF-1.

How does CJC-1295 DAC work?

Albumin-binding (DAC) GHRH analog producing sustained, multi-day elevation of GH and IGF-1.

What is the research status of CJC-1295 DAC?

CJC-1295 DAC is currently classified as discontinued, with 31 research references on record. This is for research purposes only and is not medical advice.

What is the half-life of CJC-1295 DAC?

The reported half-life of CJC-1295 DAC is 6-8 days.

Related peptides

Somatostatin

Endogenous cyclic peptide that inhibits GH, insulin, glucagon, and gastric secretion via SSTR1-5 receptors.

Ghrelin

Endogenous 28-aa 'hunger hormone' from the stomach; activates GHS-R1a to stimulate GH release and appetite.

GHRP-6

First-generation ghrelin receptor agonist hexapeptide that stimulates GH release and strongly increases appetite.

Hexarelin

Potent GHRP-family ghrelin receptor agonist with studied cardioprotective effects independent of GH release.

GHRP-2

Synthetic hexapeptide ghrelin receptor agonist that potently stimulates GH secretion; also raises appetite, cortisol, and prolactin.

Tesamorelin

Stabilized GHRH analog approved for HIV-associated lipodystrophy; reduces visceral adipose tissue via GH/IGF-1 axis stimulation.

Build on CJC-1295 DAC data programmatically

Structured peptide data, semantic search, and AI summaries via one API.

Get a free API key